In a filing, United Therapeutics Corp revealed its EVP & GENERAL COUNSEL MAHON PAUL A unloaded Company’s shares for reported $3.48 million on May 29 ’25. In the deal valued at $316.07 per share,11,000 shares were sold. As a result of this transaction, MAHON PAUL A now holds 36,781 shares worth roughly $11.73 million.
Then, PAUL MAHON bought 11,000 shares, generating $3,476,765 in total proceeds.
Before that, MAHON PAUL A sold 11,000 shares. United Therapeutics Corp shares valued at $3,246,150 were divested by the EVP & GENERAL COUNSEL at a price of $295.10 per share. As a result of the transaction, MAHON PAUL A now holds 36,781 shares, worth roughly $11.73 million.
Wells Fargo downgraded its United Therapeutics Corp [UTHR] rating to an Equal weight from a an Overweight in a research note published recently. A number of analysts have revised their coverage, including BofA Securities’s analysts, who increased its forecast for the stock in late April from “an Underperform” to “a Neutral”. Morgan Stanley also remained covering UTHR and has decreased its forecast on July 11, 2024 with a “an Equal-weight” recommendation from previously “an Overweight” rating. Goldman revised its rating on February 12, 2024. It rated UTHR as “a Neutral” which previously was an “a Sell”.
Price Performance Review of UTHR
On Friday, United Therapeutics Corp [NASDAQ:UTHR] saw its stock fall -0.47% to $318.85. Over the last five days, the stock has gained 3.28%. United Therapeutics Corp shares have fallen nearly -9.63% since the year began. Nevertheless, the stocks have risen 18.47% over the past one year. While a 52-week high of $417.82 was reached on 02/19/25, a 52-week low of $266.98 was recorded on 04/09/25. SMA at 50 days reached $301.51, while 200 days put it at $342.41.
Levels Of Support And Resistance For UTHR Stock
The 24-hour chart illustrates a support level at 315.26, which if violated will result in even more drops to 311.66. On the upside, there is a resistance level at 321.46. A further resistance level may holdings at 324.07. The Relative Strength Index (RSI) on the 14-day chart is 62.38, which indicates neutral technical sentiment, while the Moving Average Convergence Divergence (MACD) stands at 8.40, which suggests price will go up in the next trading period. Percent R suggests that price movement has been bullish at 7.28%. Stochastics %K at 92.58% indicates the stock is a selling.
The most recent change occurred on February 05, 2024 when Leerink Partners began covering the stock and recommended ‘”an Outperform”‘ rating along with a $330 price target.
